Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir

Conclusion: Viral replication decreases in patients with chronic HBV infection in the presence of NAFLD, and NAFLD had no impact on the virologic response to entecavir and tenofovir treatment

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Background/Aims: We aimed to evaluate the impact of non-alcoholic fatty liver disease (NAFLD) on viral kinetics and virologic response to tenofovir and entecavir treatment in patients with chronic hepatitis B virus (HBV) infection.Materials and Methods: This study was designed as a retrospective multicenter cohort study.

📊

Key Findings & Data:The impact of hepatosteatosis on pre-treatment serum HBV DNA levels and also on the virologic response to either tenofovir or entecavir at 6 and 12 months of therapy was investigated.

💡

Conclusion & Impact:Conclusion: Viral replication decreases in patients with chronic HBV infection in the presence of NAFLD, and NAFLD had no impact on the virologic response to entecavir and tenofovir treatment

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Özet

Background/Aims: We aimed to evaluate the impact of non-alcoholic fatty liver disease (NAFLD) on viral kinetics and virologic response to tenofovir and entecavir treatment in patients with chronic hepatitis B virus (HBV) infection.Materials and Methods: This study was designed as a retrospective multicenter cohort study. The impact of hepatosteatosis on pre-treatment serum HBV DNA levels and also on the virologic response to either tenofovir or entecavir at 6 and 12 months of therapy was investigated. Results: A total of 145 cases were involved in the study [median age 40 (18-73) years, 90 (62%) males]. In multivariate analysis, it was detected that patients with NAFLD were older and had a higher body mass index (BMI) [Odds ratio (95% confidence interval) and p-value for age were 1.040 (1.003-1.079) and 0.033 and for BMI were 1.348 (1.190-1.528) and 0.0001, respectively]. When only the 43 patients who were younger than 35.5 years old and who had a BMI less than 27.59 were investigated, serum high-density lipoprotein (HDL) levels and serum HBV DNA levels were lower in patients with NAFLD in multivariate analysis [Odds ratio (95% confidence interval) and p-values for serum HDL level and HBV DNA level were 0.864 (0.061-0.980) and 0.023 and 0.995 (0.990-0.999) and 0.025, respectively]. Totally, 57 and 75 of the patients had received entecavir and tenofovir, respectively. Conclusion: Viral replication decreases in patients with chronic HBV infection in the presence of NAFLD, and NAFLD had no impact on the virologic response to entecavir and tenofovir treatment

🔖

Cite This Article

CEYLAN, B., ARSLAN, F., BATIREL, A., FİNCANCI, M., YARDIMCI, C., FERSAN, E., PAŞAOĞLU, H. E., YILMAZ, M., MERT, A. (2016). Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 1, 42–46. https://ajindex.com/articles/411079

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (4)

Başaranoğlu M, Örmeci N. Nonalcoholic fatty liver disease: diag- nosis, pathogenesis, and management. Turk J Gastroenterol 2014; 25: 127-32. [CrossRef] Peng D, Han Y, Ding H, Wei L. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008; 23(7 Pt 1): 1082-8. [CrossRef] Poortahmasebi V, Alavian SM, Keyvani H, Norouzi M, Mahmoodi M, Jazayeri SM. Hepatic steatosis: prevalence and host/viral risk factors in Iranian patients with chronic hepatitis B infection. Asian Pac J Cancer Prev 2014; 15: 3879-84. [CrossRef] Rastogi A, Sakhuja P, Kumar A, Hissar S, Jain A, Gondal R, et al. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol 2011; 54: 454-9. [CrossRef] Lesmana LA, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its associa- tion with disease severity. Acta Medica Indones 2012; 44: 35-9.
Zheng R, Xu C, Jiang L, Dou A, Zhou K, Lu L. Predictors of hepatic ste- atosis in HBeAg-negative chronic hepatitis B patients and their diag- nostic values in hepatic fibrosis. Int J Med Sci 2010; 7: 272-7. [CrossRef] Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroen- terol Hepatol 2011; 26: 1361-7. [CrossRef] Shi J, Fan J, Wu R, Gao X, Zhang L, Wang H. [Prevalence and risk factors of hepatic steatosis in patients with chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi 2008; 16: 519-23.
Jiang C-Y, Zeng W-Q, Chen Y-X, Dai F-H, Jiang P. [Effect of HBV on the expression of SREBP in the hepatocyte of chronic hepatitis B patients combined with hepatic fatty change]. Zhonghua Gan Zang Bing Za Zhi 2011; 19: 608-13.
Minakari M, Molaei M, Shalmani HM, et al. Liver steatosis in pa- tients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol 2009; 21: 512-6. [CrossRef] Bondini S, Kallman J, Wheeler A, et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int 2007; 27: 607- 11. [CrossRef] Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012; 56: 533-40. [CrossRef] Xu Q, Jie Y, Shu X, Chen L, Cao H, Li G. [Relationship of fatty liver with HBV infection, hyperlipidemia and abnormal a